Results 61 to 70 of about 2,198,135 (358)

Multi‐omic characterization of consensus molecular subtype 1 (CMS1) colorectal cancer with dampened immune response improves precision medicine

Molecular Oncology, EarlyView.
This study highlights the importance of multi‐omic analyses in characterizing colorectal cancers. Indeed, our analysis revealed a rare CMS1 exhibiting dampened immune activation, including reduced PD‐1 expression, moderate CD8+ T‐cell infiltration, and suppressed JAK/STAT pathway.
Livia Concetti, Manuel Scimeca, Julia Bischof, Jonathan Woodsmith, Massimiliano Agostini, Cristina Fiorani, Yufang Shi, Eleonora Candi, Gerry Melino, Alessandro Mauriello, Giuseppe S. Sica   +10 more
wiley   +1 more source

MONOCLONAL ANTIBODY FOR MULTIPLE SCLEROSIS TREATMENT

Медицинский совет, 2017
Monoclonal antibodies are widely used in various fields of modern medicine, for example, in oncology, rheumatology, gastroenterology, transplantation.
E. V. Popova
doaj   +1 more source

Signaling dependent and independent mechanisms in pemphigus vulgaris blister formation. [PDF]

PLoS ONE, 2012
Pemphigus vulgaris (PV) is an autoimmune epidermal blistering disease caused by autoantibodies directed against the desmosomal cadherin desmoglein-3 (Dsg3). Significant advances in our understanding of pemphigus pathomechanisms have been derived from the
Masataka Saito, Sara N Stahley, Christopher Y Caughman, Xuming Mao, Dana K Tucker, Aimee S Payne, Masayuki Amagai, Andrew P Kowalczyk   +7 more
doaj   +1 more source

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond

Immunological Reviews, 2016
CD38 is a multifunctional cell surface protein that has receptor as well as enzyme functions. The protein is generally expressed at low levels on various hematological and solid tissues, while plasma cells express particularly high levels of CD38.
N. Donk, M. Janmaat, T. Mutis, J. J. Lammerts van Bueren, T. Ahmadi, A. Sasser, H. Lokhorst, P. Parren   +7 more
semanticscholar   +1 more source

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Science, 2020
Protective neutralizing antibodies Antibodies produced by survivors of coronavirus disease 2019 (COVID-19) may be leveraged to develop therapies. A first step is identifying neutralizing antibodies, which confer strong protection against severe acute ...
T. Rogers, Fangzhu Zhao, Deli Huang, N. Beutler, Alison Burns, Wan-ting He, Oliver Limbo, C. Smith, G. Song, J. Woehl, Linlin Yang, R. Abbott, Sean Callaghan, Elijah Garcia, Jonathan Hurtado, M. Parren, Linghang Peng, S. Ramirez, James Ricketts, M. Ricciardi, Stephen A. Rawlings, N. Wu, M. Yuan, Davey M. Smith, D. Nemazee, J. Teijaro, J. Voss, I. Wilson, R. Andrabi, Bryan S. Briney, E. Landais, D. Sok, J. Jardine, D. Burton   +33 more
semanticscholar   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

Molecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes   +17 more
wiley   +1 more source

Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system

Cardio-Oncology, 2023
Background Antineoplastic monoclonal antibodies (mAbs), such as trastuzumab, bevacizumab, and pertuzumab have been the mainstay of therapy in cancer patients.
Abdulrazaq S. Al-Jazairi, Nahlah Bahammam, Dhai Aljuaid, Lama Almutairi, Shroog Alshahrani, Norah Albuhairan, Peter M. B. Cahusac, Ghazwa B. Korayem   +7 more
doaj   +1 more source

Development of therapeutic antibodies for the treatment of diseases

Journal of Biomedical Sciences, 2020
It has been more than three decades since the first monoclonal antibody was approved by the United States Food and Drug Administration (US FDA) in 1986, and during this time, antibody engineering has dramatically evolved.
Ruei-Min Lu, Yu-Chyi Hwang, I. Liu, Chi-Chiu Lee, Han-zen Tsai, Hsin-Jung Li, Han‐Chung Wu   +6 more
semanticscholar   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source